On Jun 27, 2018 Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) Shorts Rose By 21.08%

June 27, 2018 - By Nellie Deboer

Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) noted an increase of 21.08% in shorted shares. FINRA published shorted shares of URGN’s total 236,100 shares. The up change of 21.08% from 195,000 shares was reported. With Average volume 120,000, URGN’s previous position will take 2 days to restore. 2.77% is Urogen Pharma LTD. – Ordinary Shares float short.

The stock decreased 2.38% or $1.2 during the last trading session, touching $49.27.Currently UroGen Pharma Ltd. is uptrending after 228.14% change in last June 27, 2017. URGN has also 76,670 shares volume. URGN outperformed by 215.57% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies.The firm is valued at $762.40 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy.Last it reported negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

For more UroGen Pharma Ltd. (NASDAQ:URGN) news published briefly go to: Nasdaq.com, Nasdaq.com, Streetinsider.com, Globenewswire.com or Multichannel.com. The titles are as follows: “UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award” published on June 13, 2018, “UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference” on May 29, 2018, “UroGen Pharma (URGN) Names Stephen Mullennix Interim CFO, Replacing Gary Titus” with a publish date: June 05, 2018, “Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and …” and the last “Qwilt Appoints Yoni Mizrahi as Chief Financial Officer” with publication date: June 21, 2018.

UroGen Pharma Ltd. (NASDAQ:URGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: